Type 2 Diabetes

Mounjaro was more effective than other type 2 diabetes drugs at helping clinical trial participants control blood sugar and lose weight, the FDA reports.

A newly vetted set of BMI diagnosis thresholds can help clinicians catch diabetes earlier in higher risk groups, investigators say.

Among individuals with type 2 diabetes, country-standardized cognitive score may predict risk for cardiovascular events

The SGLT2 inhibitor Farxiga substantially reduced risk for worsening heart failure events and death in frail patients, a new analysis finds. The more frail the patient, the more benefits seen.

Life expectancy gains seen with reducing HbA1c, SBP, LDL-C, and BMI among individuals with type 2 diabetes

GLP-1 RA treatment linked to increased risk, especially in trials for weight loss, and with higher doses and longer duration of use

Despite being discouraged in the elderly, a facilities study has found that sliding scale insulin therapy is used in 21% of newly admitted residents who receive the drug for type 2 diabetes and is continued...

Fully 40% of residents with type 2 diabetes in a large VA nursing home study continued to receive insulin and other medications that increase hypoglycemia risk, even after their blood tests suggested overtreatment.

Originally approved as a glucose control drug for patients with type 2 diabetes, Jardiance has more recently proven effective in reducing mortality and hospitalization in some heart failure patients.

Higher body-mass index levels were associated with an increased risk of diabetic kidney disease and decreased kidney filtration rate levels in nearly 4,000 people with type 2 diabetes.